Scabies: Diagnostic and Therapeutic Update

Abstract

Background

Scabies is globally ubiquitous and is a significant health issue for institutions, the economically disenfranchised, resource-poor areas, and for those with weakened immune systems. Topicals are usually effective, but are cumbersome and expensive to use in large populations and for those nonadherent to topicals. Oral ivermectin became available in Canada for the off-label treatment of scabies in the fall 2018.

Objectives

To review the diagnosis and management of scabies. Dose schedules and concomitant management measures are outlined for scabies simplex and for crusted scabies. Ivermectin use is outlined.

Methods

Medline, colleague discussions, practice review, and experience from managing scabies in institutions.

Results

Oral ivermectin is safe, easier to use, cheaper, more effective, and more economical than topicals in widespread institutional scabies, for those nonadherent to topicals, and in crusted scabies.

Conclusions

Oral ivermectin is the treatment of choice in large populations, the nonadherent, and for crusted scabies. Oral ivermectin is produced by Merck Canada as Stromectol 3 mg. The treatment dose for noncrusted scabies is 200 µg/kg, taken in a single dose with food. For example, 15 mg (5 tablets) for a 70 kg person. Retreat in 10-14 days to enhance effectiveness, and perhaps to reduce scabicide resistance.

Keywords

scabies crusted scabies institutional scabies ivermectin permethrin population outbreaks

Get full access to this article

View all access options for this article.

References

Chandler

DJ.

Fuller

. A review of scabies: an infestation more than skin deep. Dermatology. 2019;235(2):79-90.doi:10.1159/000495290

30544123

Wheat

CM.

Burkhart

CN.

Burkhart

et al. Scabies, other mites, and pediculosis. In: Goldsmith

LA.

Katz

SI.

Gilchrest

BA.

, eds. Fitzpatrick’s Dermatology in General Medicine. 8th ed; 2015.

Burkhart

CN.

Buckhart

CG.

Morrell

. Infestations. In: Bologna

JL.

Schaffer

JV.

Cerroni

, eds. Dermatology. vol 2. 4th ed; 2017:1503-1506.

Salavastru

CM.

Chosidow

Boffa

MJ.

Janier

Tiplica

. European guideline for the management of scabies. J Eur Acad Dermatol Venereol. 2017;31(8):1248-1253.doi:10.1111/jdv.14351

28639722

Thomas

Coates

SJ.

Engelman

Chosidow

Chang

. Ectoparasites: scabies. J Am Acad Dermatol. 2020;82(3):533-548.doi:10.1016/j.jaad.2019.05.109

31310840

Rosumeck

Nast

Dressler

. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev. 2018;4(4):CD012994. doi:10.1002/14651858.CD012994

29608022

Currie

BJ.

McCarthy

. Permethrin and ivermectin for scabies. N Engl J Med. 2010;362(8):717-725.doi:10.1056/NEJMct0910329

20181973

Dupuy

Dehen

Bourrat

et al. Accuracy of standard dermoscopy for diagnosing scabies. J Am Acad Dermatol. 2007;56(1):53-62.doi:10.1016/j.jaad.2006.07.025

17190621

Banerji

Society

. First nations, Inuit and Metis health Committee scabies position statement. Pediatr Child Health. 2015;20(7):395-398.

10.

Currie

Davis

. Crusted scabies grading scale and treatment plan. Department of health and families Northern Territory government (Australia). Am J Trop Med Hyg. 2005;3(5):911-914.

11.

Hay

RJ.

Steer

AC.

Engelman

Walton

. Scabies in the developing world―its prevalence, complications, and management. Clin Microbiol Infect. 2012;18(4):313-323.doi:10.1111/j.1469-0691.2012.03798.x

22429456

12.

Karimkhani

Colombara

DV.

Drucker

et al. The global burden of scabies: a cross-sectional analysis from the global burden of disease study 2015. Lancet Infect Dis. 2017;17(12):1247-1254.doi:10.1016/S1473-3099(17)30483-8

28941561

13.

Mbuagbaw

Bisseck

Ozoh

Etienne

et al. The epidemic of scabies in Yaounde. The Internet Journal of Dermatology. 2005;4(2)doi:10.5580/aa2

14.

Tolkachjov

SN.

Davis

MDP.

Yiannias

. Crusted (Norwegian) scabies: nine-month course with iatrogenic immunosuppression. J Drugs Dermatol. 2018;17(10):1131-1132.30365596

15.

Engelman

Fuller

Steer

International Alliance for the Control of Scabies Delphi panel . Consensus criteria for the diagnosis of scabies: a Delphi study of international experts. PLoS Negl Trop Dis. 2018;12(5):e0006549. doi:10.1371/journal.pntd.0006549

29795566

16.

Engelman

Yoshizumi

Hay

et al. The 2020 international alliance for the control of scabies consensus criteria for the diagnosis of scabies. Br J Dermatol. 2020 [published online ahead of print February 08, 2020].

17.

Micali

Lacarrubba

Verzì

AE.

Nasca

. Low-cost equipment for diagnosis and management of endemic scabies outbreaks in underserved populations. Clin Infect Dis. 2015;60(2):327-329.doi:10.1093/cid/ciu826

25344538

18.

Romani

Whitfeld

MJ.

Koroivueta

et al. Mass drug administration for scabies—2 years of follow-up. N Engl J Med Overseas Ed. 2019;381(2):186-187.doi:10.1056/NEJMc1808439

19.

Romani

Marks

Sokana

et al. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lancet Infect Dis. 2019;19(5):510-518.doi:10.1016/S1473-3099(18)30790-4

30956111

20.

Matthewman

Manego

RZ.

Dimessa Mbadinga

et al. A randomized controlled trial comparing the effectiveness of individual versus household treatment for scabies in Lambaréné, Gabon. PLoS Negl Trop Dis. 2020;14(6):e0008423. doi:10.1371/journal.pntd.0008423

32589632

21.

Facts

. Reregistration Eligibility Decision (RED) Fact Sheet. U.S. Environmental Protection Agency, Office of Prevention, Pesticide and Toxic Substances, Office of Pesticide Programs, U.S, Government Printing Office; 2007.

22.

Nolan

Kamrath

Levitt

toxicity

. Lindane toxicity: a comprehensive review of the medical literature. Pediatr Dermatol. 2012;29(2):141-146.doi:10.1111/j.1525-1470.2011.01519.x

21995612

23.

Richards

. Update on intralesional steroid: focus on dermatoses. J Cutan Med Surg. 2010;14(1):19-23.doi:10.2310/7750.2009.08082

20128986

24.

Regulatory Decision Summary- Stromectol-Health Canada. Accessed September 05, 2018. https://hpr.hres.ca>reg-content>regulatory-decision-summary-detail

25.

Merck Canada Inc . Product Monograph. Including patient Medication Information. Stromectol (ivermectin tablet, USP 3 mg); 2018.

26.

Barkwell

Shields

. Deaths associated with ivermectin treatment of scabies. Lancet. 1997;349(9059):1144-1145.doi:10.1016/S0140-6736(05)63020-6

9113017

27.

Middleton

Walker

SL.

House

Head

MG.

Cassel

. Ivermectin for the control of scabies outbreaks in the UK. Lancet. 2019;394(10214):2068-2069.doi:10.1016/S0140-6736(19)32619-4

31818402

28.

World Health Organization (WHO) . WHO model list of essential medicines (19th list). http://www.who.int/medicines/publications/essentialmedicines

29.

CDC . Scabies - Institutional Settings - Control - CDC. Accessed November 2, 2010. www.cdc.gov › parasites › scabies › health_professionals

30.

Turner

SA.

Maclean

JD.

Fleckenstein

Greenaway

. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am J Trop Med Hyg. 2005;73(5):911-914.doi:10.4269/ajtmh.2005.73.911

16282302

31.

Lim

. Institutional scabies. DermNet NZ. 2010

32.

Chong

YO.

Vasanwala

. Infected with scabies again? focus in management in long-term care facilities. Diseases. 2019;7(1):3.

33.

Mounsey

KE.

Murray

HC.

King

Oprescu

. Retrospective analysis of institutional scabies outbreaks from 1984 to 2013: lessons learned and moving forward. Epidemiol Infect. 2016;144(11):2462-2471.doi:10.1017/S0950268816000443

27019288

34.

Chosidow

. Scabies and pediculosis. Lancet. 2000;355(9206):819-826.doi:10.1016/S0140-6736(99)09458-1

10711939

35.

Lynar

Currie

BJ.

Baird

. Scabies and mortality. Lancet Infect Dis. 2017;17(12):1234. doi:10.1016/S1473-3099(17)30636-9

29173877